Cargando…

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma

INTRODUCTION: Although PD-1/L1 mAb has demonstrated clinical benefits in certain cancer types, low response rate and resistance remain the main challenges for the application of these immune checkpoint inhibitors (ICIs). 4-1BB is a co-stimulator molecule expressed in T cells, which could enhance T c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yichen, Zhang, Xuyao, Xu, Caili, Nan, Yanyang, Fan, Jiajun, Zeng, Xian, Kwon, Byoung S., Ju, Dianwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762552/ https://www.ncbi.nlm.nih.gov/pubmed/36544785 http://dx.doi.org/10.3389/fimmu.2022.1004475

Ejemplares similares

TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
por: Xu, Caili, et al.
Publicado: (2023)

Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E
por: Wang, Yichen, et al.
Publicado: (2018)

Editorial: Combinational immunotherapy of cancer: novel targets, mechanisms, and strategies
por: Nan, Yanyang, et al.
Publicado: (2023)

Innate Immunity in Cancer Biology and Therapy
por: Zhang, Yuxia, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer
por: Xu, Caili, et al.
Publicado: (2022)

Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy
por: Xu, Caili, et al.
Publicado: (2022)

Editorial: Community series in combinational immunotherapy of cancer: novel targets, mechanisms, and strategies, volume II
por: Xu, Caili, et al.
Publicado: (2023)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
por: Puigdelloses, Montserrat, et al.
Publicado: (2021)

Correction: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Publicado: (2021)

Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
por: Zhang, Jinghui, et al.
Publicado: (2021)

Correction: Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
por: Zhang, Jinghui, et al.
Publicado: (2023)

Inhibition of Hedgehog signaling ameliorates foam cell formation by promoting autophagy in early atherosclerosis
por: Zhang, Yuting, et al.
Publicado: (2023)

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma
por: Ying, Zhitao, et al.
Publicado: (2022)

An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
por: Muik, Alexander, et al.
Publicado: (2022)

NOD-Like Receptor Protein 3 Inflammasome-Dependent IL-1β Accelerated ConA-Induced Hepatitis
por: Luan, Jingyun, et al.
Publicado: (2018)

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity
por: Cheng, Lian-sheng, et al.
Publicado: (2022)

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
por: Bartkowiak, Todd, et al.
Publicado: (2015)

IL‐22‐mediated renal metabolic reprogramming via PFKFB3 to treat kidney injury
por: Chen, Wei, et al.
Publicado: (2021)

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
por: Fernandez-Rodriguez, Laura, et al.
Publicado: (2023)

Interleukin-22 Attenuated Renal Tubular Injury in Aristolochic Acid Nephropathy via Suppressing Activation of NLRP3 Inflammasome
por: Wang, Shaofei, et al.
Publicado: (2019)

Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
por: Song, Chang, et al.
Publicado: (2014)

Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade
por: Mueller, Antonia MS, et al.
Publicado: (2014)

Correction: Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
Publicado: (2023)

Regulating autophagy facilitated therapeutic efficacy of the sonic Hedgehog pathway inhibition on lung adenocarcinoma through GLI2 suppression and ROS production
por: Fan, Jiajun, et al.
Publicado: (2019)

Interleukin-22 drives a metabolic adaptive reprogramming to maintain mitochondrial fitness and treat liver injury
por: Chen, Wei, et al.
Publicado: (2020)

An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
por: Cheng, Lian-sheng, et al.
Publicado: (2023)

A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease
por: Hu, Xiaozhi, et al.
Publicado: (2022)

Tethering Interleukin-22 to Apolipoprotein A-I Ameliorates Mice from Acetaminophen-induced Liver Injury
por: Chen, Wei, et al.
Publicado: (2017)

Autophagy Plays a Critical Role in ChLym-1-Induced Cytotoxicity of Non-Hodgkin’s Lymphoma Cells
por: Fan, Jiajun, et al.
Publicado: (2013)

Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma
por: Capone, Emily, et al.
Publicado: (2017)

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
por: Vinay, Dass S., et al.
Publicado: (2014)

HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
por: Zhang, Jibin, et al.
Publicado: (2020)

Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect
por: Oya, Kazumasa, et al.
Publicado: (2021)

Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8(+) T cells and the exclusion of Treg cells
por: Wang, Rui, et al.
Publicado: (2022)

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
por: Ho, Winson S., et al.
Publicado: (2018)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
por: Kowalsky, Stacy J., et al.
Publicado: (2018)

Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1
por: Lee, Chan-Hyeong, et al.
Publicado: (2022)

Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors
por: Mascarelli, Daniele E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eo320juhls26lcu3jjblmtv2b8